KWKarin Wind-Mark

Karin Wind-Mark

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karin Wind-Mark has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism

    by Astrid F. Feiten, Kilian Dahm, Kai Schlepckow, Bettina van Lengerich, Jung H. Suh, Anika Reifschneider, Benedikt Wefers, Laura M. Bartos, Karin Wind-Mark, Lis de Weerd, et al.

    Triggering receptor expressed on myeloid cells 2 (TREM2) is a central regulator of microglial activity and loss-of-function coding variants are major risk factors for late onset Alzheimer’s disease (LOAD). To better understand the molecular and functional changes associated with TREM2 signalling in microglia, we generated a TREM2 reporter mouse. In APP transgenic animals, bulk RNA-sequencing of isolated microglia sorted based on reporter expression highlighted TREM2 level-related changes in major immunometabolic pathways, and enrichment of genes in oxidative phosphorylation and cholesterol metabolism in microglia with increased TREM2 expression. Metabolic and lipidomic profiling of sorted microglia showed that, independent of Aβ pathology, TREM2 expression correlated with signatures consistent with increased cellular redox, energetics, and cholesterol homoeostasis. In accordance, metabolic activity correlated with phagocytic capacity. Finally, we performed chronic treatment with a TREM2 agonist antibody and identified a window of TREM2 expression where microglia are most responsive, thereby informing clinical applications of TREM2 agonists.


  • Open Access

    Early Locus Coeruleus noradrenergic axon loss drives olfactory dysfunction in Alzheimer’s disease

    by Carolin Meyer, Theresa Niedermeier, Paul L. C. Feyen, Felix L. Strübing, Boris-Stephan Rauchmann, Katerina Karali, Johanna Gentz, Yannik E. Tillmann, Nicolas F. Landgraf, Svenja-Lotta Rumpf, et al.

    Alzheimer’s disease (AD) often begins with non-cognitive symptoms such as olfactory deficits, which can predict later cognitive decline, though the mechanisms remain unclear. Pathologically, the brainstem locus coeruleus (LC), the main source of the neurotransmitter noradrenalin (NA) modulating olfactory information processing is affected early. Here we show early and distinct loss of noradrenergic input to the olfactory bulb (OB) coinciding with impaired olfaction in an AD mouse model, before appearance of amyloid plaques. Mechanistically, OB microglia recognize and phagocytose LC axons. Reducing phagocytosis genetically preserves LC axons and olfaction. Prodromal AD patients display elevated TSPO-PET signals in the OB, similarly to App NL-G-F mice. We further confirm early LC axon degeneration in post-mortem OBs in patients with early AD. Our findings reveal a mechanism linking early LC damage to hyposmia in AD, suggesting olfactory testing and neurocircuit imaging for early diagnosis and enable timely therapeutic intervention for Alzheimer’s disease.


  • Myeloid cell–specific loss of NPC1 in mice recapitulates microgliosis and neurodegeneration in patients with Niemann-Pick type C disease

    by Lina Dinkel, Selina Hummel, Valerio Zenatti, Mariagiovanna Malara, Yannik Tillmann, Alessio Colombo, Laura Sebastian Monasor, Jung H. Suh, Todd Logan, Stefan Roth, et al.

    Niemann-Pick type C (NPC) disease is an inherited lysosomal storage disorder mainly driven by mutations in the NPC1 gene, causing lipid accumulation within late endosomes/lysosomes and resulting in progressive neurodegeneration. Although microglial activation precedes neuronal loss, it remains elusive whether loss of the membrane protein NPC1 in microglia actively contributes to NPC pathology. In a mouse model with depletion of NPC1 in myeloid cells, we report severe alterations in microglial lipidomic profiles, including the enrichment of bis(monoacylglycero)phosphate, increased cholesterol, and a decrease in cholesteryl esters. Lipid dyshomeostasis was associated with microglial hyperactivity, marked by an increase in translocator protein 18 kDa (TSPO). These hyperactive microglia initiated a pathological cascade resembling NPC-like phenotypes, including a shortened life span, motor impairments, astrogliosis, neuroaxonal pathology, and increased neurofilament light chain (NF-L), a neuronal injury biomarker. As observed in the mouse model, patients with NPC showed increased NF-L in the blood and microglial hyperactivity, as visualized by TSPO-PET imaging. Reduced TSPO expression in blood-derived macrophages of patients with NPC was measured after N -acetyl- l -leucine treatment, which has been recently shown to have beneficial effects in patients with NPC, suggesting that TSPO is a potential marker to monitor therapeutic interventions for NPC. Conclusively, these results demonstrate that myeloid dysfunction, driven by the loss of NPC1, contributes to NPC disease and should be further investigated for therapeutic targeting and disease monitoring.


  • Open Access

    Table 1 from Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome

    by Laura M. Bartos, Stefanie Quach, Valerio Zenatti, Sabrina V. Kirchleitner, Jens Blobner, Karin Wind-Mark, Zeynep Ilgin Kolabas, Selin Ulukaya, Adrien Holzgreve, Viktoria C. Ruf, et al.

    Characteristics of the cohort.

  • Open Access

    Figure 2 from Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome

    by Laura M. Bartos, Stefanie Quach, Valerio Zenatti, Sabrina V. Kirchleitner, Jens Blobner, Karin Wind-Mark, Zeynep Ilgin Kolabas, Selin Ulukaya, Adrien Holzgreve, Viktoria C. Ruf, et al.

    Contralateral TSPO-PET signal elevation is associated with tumor phenotype and localization. A and B, Correlation of contralateral TSPO-PET signals in patients with glioblastoma (n = 38) with the TSPO-PET signal of the tumor (A) and the tumor volume in TSPO-PET, FET-PET (B, left), and MRI (B, right). C, Examples of TSPO-PET images derived from patients with distinct tumor extent and TSPO expression in PET indicate distinct contralateral PET signal elevation. D, Overall correlation between corresponding areas of the tumor and the contralateral hemispheres including all 123 brain sub-regions of each individual patient. E, Correlation of regionally defined tumor seed regions with TSPO-PET signals of the 123 sub-regions in the contralateral hemisphere. Surface projection of tumor seed localization (top rows: seed region, colored in black) and corresponding contralateral coefficients of correlation (bottom rows). IFG, inferior-frontal gyrus; ITG, inferior-temporal gyrus; MesTemp, mesio-temporal; MFG, mid-frontal gyrus; Motor, motor area; MTG, mid-temporal gyrus; OFG, orbitofrontal gyrus; SFG, superior-frontal gyrus; STG, superior-temporal gyrus. F, Correlation of both hemispheres within 15 previously defined anatomically and functionally connected brain regions. Highest coefficients of correlation are colored in red, significant correlations are highlighted by thick boundaries.

  • Open Access

    Figure 4 from Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome

    by Laura M. Bartos, Stefanie Quach, Valerio Zenatti, Sabrina V. Kirchleitner, Jens Blobner, Karin Wind-Mark, Zeynep Ilgin Kolabas, Selin Ulukaya, Adrien Holzgreve, Viktoria C. Ruf, et al.

    Back-translation into a glioblastoma mouse model pinpoints myeloid cells as the cellular source of contralateral TSPO-PET signal elevations. A, Glioblastoma mice (n = 15) show higher TSPO-PET signal in the contralateral hemisphere compared to sham injected animals (n = 14). B, Coronal slices of group average TSPO-PET images of SB28 glioblastoma mice (top row; n = 15) and sham injected mice (bottom row; n = 14). Analyzed planes are indicated upon a CT template. Arrows point to the PET signal elevation in the contralateral hemisphere of SB28 mice. Tumor hemisphere is blurred. C, Whole brain tumor seed correlation analysis shows dependency of contralateral TSPO-PET signals (white arrows) from tumor TSPO-PET signals in SB28 mice (n = 15). Tumor TSPO-PET signals were extracted using a spherical volume of interest with 1.5 mm diameter and included as a seed in a voxel-wise statistical parametric mapping regression model. D, CD11b positive myeloid cells of the contralateral hemisphere of glioblastoma mice (n = 13) show higher single-cell TSPO tracer uptake than myeloid cells of sham injected (n = 14) or healthy control mice (n = 8; left). Non-myeloid cells show no difference in TSPO tracer uptake between the three conditions (right). E and F, Immunohistochemistry shows higher myeloid cell abundance and increased TSPO in IBA1 positive myeloid cells in contralateral hemispheres of SB28 glioblastoma mice (n = 3) compared to sham (n = 4). G, qPCR was used to exclude infiltration of SB28 glioblastoma cells into the contralateral hemispheres in SB28 glioblastoma mice (n = 8; left). Tumor tissue was used as a positive control. While tumor cells could only be detected in the tumor tissue, TSPO expression was observed in contralateral hemispheres of SB28 glioblastoma mice and exceeded TSPO expression in sham injected (n = 4) and healthy control mice (n = 4, right). (Adapted from an image created with BioRender.com.)

  • Open Access

    Figure 1 from Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome

    by Laura M. Bartos, Stefanie Quach, Valerio Zenatti, Sabrina V. Kirchleitner, Jens Blobner, Karin Wind-Mark, Zeynep Ilgin Kolabas, Selin Ulukaya, Adrien Holzgreve, Viktoria C. Ruf, et al.

    Elevated TSPO-PET signals in the non-lesional hemisphere of patients with glioblastoma. A, Patient selection process. Patients receiving TSPO-PET imaging at initial diagnosis of glioma were allocated. Patients with unilateral manifestation of glioblastoma (WHO IV; n = 41) or isocitrate dehydrogenase mutant astrocytoma WHO grade 2 (IDHmut astrocytoma WHO 2; n = 7) at the time of PET were selected for further analysis. B, Patients with newly diagnosed glioblastoma but not patients with IDHmut astrocytoma WHO 2 indicate higher TSPO-PET signal in the contralateral hemisphere compared to healthy controls. Images represent examples of TSPO-PET images of patients with newly diagnosed glioblastoma (left) and IDHmut astrocytoma WHO 2 (middle) in comparison to a healthy control (right). C, Surface projections and axial slices of the group average contralateral TSPO-PET signal of patients with glioblastoma, IDHmut astrocytoma WHO 2, and healthy controls. The non-lesional hemispheres were parcellated into 123 sub-regions using the Brainnetome Atlas. Axial slices show TSPO-PET signals of basal ganglia regions (masked cortical regions). D, Significant TSPO-PET signal elevation in brain regions of the contralateral hemisphere of patients with glioblastoma but not with IDHmut astrocytoma WHO 2 compared to healthy controls. E, Pronounced contralateral TSPO expression in orbito-frontal, superior-temporal, mid-temporal, and mesio-temporal regions of patients with glioblastoma. *, P < 0.01.

  • Open Access

    Supplementary Data 1 from Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome

    by Laura M. Bartos, Stefanie Quach, Valerio Zenatti, Sabrina V. Kirchleitner, Jens Blobner, Karin Wind-Mark, Zeynep Ilgin Kolabas, Selin Ulukaya, Adrien Holzgreve, Viktoria C. Ruf, et al.

    Supplementary Figures 1, 2 Supplementary Tables 1 - 3 inlucing Representativeness of Study Participants" supplementary table (Supplementary Table 1)

  • Open Access

    Figure 5 from Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome

    by Laura M. Bartos, Stefanie Quach, Valerio Zenatti, Sabrina V. Kirchleitner, Jens Blobner, Karin Wind-Mark, Zeynep Ilgin Kolabas, Selin Ulukaya, Adrien Holzgreve, Viktoria C. Ruf, et al.

    Contralateral hemispheres of SB28 glioblastoma mice indicate signatures of disease-associated myeloid cells and immunosuppression. A, Volcano plot highlights genes with significant upregulation and downregulation in the contralateral hemisphere of SB28 glioblastoma mice (red and blue, respectively) compared to sham. B, qPCR reveals higher expression of genes related to an inflammatory myeloid cell state in contralateral hemispheres of SB28 glioblastoma mice in contrast to sham. C, Illustration of the 50 pathways with highest elevation in immune cells of the contralateral hemisphere of SB28 glioblastoma mice (informed by IPA). Note that 40 out of the 50 pathways with highest activation were related to cell migration (phagocytes, leukocytes), phagocytosis, and immune cell activation (indicated in blue). D, IPA network analysis based on altered gene expression signatures in contralateral hemispheres of SB28 glioblastoma mice in contrast to sham. Depicted is a network plot showing TSPO-mediated associations with poor prognosis (e.g., CCL2) and immunosuppression (e.g., CHI3L1).

  • Open Access

    Figure 3 from Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome

    by Laura M. Bartos, Stefanie Quach, Valerio Zenatti, Sabrina V. Kirchleitner, Jens Blobner, Karin Wind-Mark, Zeynep Ilgin Kolabas, Selin Ulukaya, Adrien Holzgreve, Viktoria C. Ruf, et al.

    Contralateral TSPO-PET signal elevation is associated with persisting epileptic seizures and worse overall survival. A, Contralateral TSPO-PET shows no quantitative difference between patients presenting with (n = 20) and without (n = 20) epileptic seizures at inital diagnosis (top). Significant increase of contralateral TSPO expression in patients experiencing persisting epileptic seizures after treatment of the primary tumor site (n = 8) compared to patients with discontinued seizures (n = 12; bottom). B, Heatmap of contralateral TSPO-PET signal in anatomically and functionally predefined brain regions (n = 15) of all patients experiencing epileptic seizures at initial diagnosis highlights two patients (age: in their 70s) with strongest contralateral TSPO expression. Coronal slices of TSPO-PET of these two patients are illustrated in comparison to group average images of patients with discontinued and persisting epileptic seizures after tumor therapy. White arrows point toward the tumor. C, Patients with persisting epileptic seizures indicate significant signal elevation in several contralateral brain regions with predominance in motor cortex, mesial temporal lobe, and occipital lobe compared to patients with discontinued epileptic seizures. *, P < 0.01. D, Matrix of regional TSPO-PET inter-correlation coefficients in comparison of patients with discontinued and persisting seizures as well as controls. Single boxes indicate interregional Pearson’s R. E, Significant increase of the contralateral TSPO-PET signal in patients with short overall survival (≤10.7 months; median split). F, High contralateral TSPO-PET signal (>0.88 SUVr; median split) at initial diagnosis is associated with worse overall survival in patients with glioblastoma. Multivariate Cox regression was adjusted for age, glucocorticoid medication, subsequent radiotherapy, and TSPO-PET signal of the tumor. **, P < 0.01. G and H, Distinct predictive value of contralateral TSPO-PET signal in different sub-regions on overall survival. *, P < 0.05.